The prevalence of TP53 mutation and primary resistance mechanisms in short-term responders to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21237-e21237
Author(s):  
Yun Fan ◽  
Xiaoling Tong ◽  
Junrong Yan ◽  
Xue Wu ◽  
Yang Shao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Tp53 Mutation ◽  
Kinase Inhibitors ◽  
Resistance Mechanisms ◽  
Small Cell ◽  
Small Cell Lung ◽  
Short Term ◽  
Primary Resistance ◽  
Egfr Tyrosine Kinase Inhibitors

scholarly journals Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

2008 ◽  
Vol 19 (9) ◽  
pp. 1605-1612 ◽  
Author(s):  
P.A. Zucali ◽  
M.G. Ruiz ◽  
E. Giovannetti ◽  
A. Destro ◽  
M. Varella-Garcia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Kinase Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Egfr Tyrosine Kinase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document